Posttreatment Surveillance in Patients with Prolonged Disease-Free Survival After Resection of Colorectal Liver MetastasisReportar como inadecuado

Posttreatment Surveillance in Patients with Prolonged Disease-Free Survival After Resection of Colorectal Liver Metastasis - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Annals of Surgical Oncology

, Volume 23, Issue 12, pp 3999–4007

First Online: 08 July 2016Received: 11 February 2016DOI: 10.1245-s10434-016-5388-8

Cite this article as: Galjart, B., van der Stok, E.P., Rothbarth, J. et al. Ann Surg Oncol 2016 23: 3999. doi:10.1245-s10434-016-5388-8


IntroductionPosttreatment surveillance protocols most often endure for 5 years after resection of colorectal liver metastasis CRLM. Most recurrences happen within 3 years after surgical removal of the tumour. This study analysed the need of surveillance for patients with at least 3 years of disease-free survival after potentially curative resection of CRLM.

MethodsA single-centre, retrospective analysis of all consecutive patients who underwent treatment for CRLM with curative intent between 2000 and 2011.

ResultsIn total, 152 of 545 patients 28 % remained disease-free for 3 years after successful resection of the CRLM. The estimated recurrence rate after 10 years of follow-up in this group of 152 patients was 27 %. More than half of these patients 55 % could be treated with curative intent for their recurrences. Multivariable analysis revealed that the nodal status of the primary tumour is of significant prognostic value for developing recurrences after 3 years of disease-free survival. A disease-free interval of less than 12 months between resection of primary tumour and detection of CRLM shows a trend towards significance. Both factors were used to create a risk score, showing that patients with a low-risk profile node-negative status and a disease-free interval <12 months have an estimated recurrence rate of 5 % and might not benefit from intensive surveillance beyond 3 years of follow-up without a recurrence.

ConclusionsThe currently developed risk score shows that follow-up can be stopped in a specific subgroup 3 years after treatment for their CRLM with curative intent.

Boris Galjart and Eric P. van der Stok authors have contributed equally.

Electronic supplementary materialThe online version of this article doi:10.1245-s10434-016-5388-8 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Boris Galjart - Eric P. van der Stok - Joost Rothbarth - Dirk J. Grünhagen - Cornelis Verhoef


Documentos relacionados